Evidence map›Paper›PMID 31547585›Full record

ArticleViruses2019

Cytokine Effects on the Entry of Filovirus Envelope Pseudotyped Virus-Like Particles into Primary Human Macrophages.

Tzanko S Stantchev, Autumn Zack-Taylor, Nicholas Mattson, Klaus Strebel, Christopher C Broder, Kathleen A Clouse

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Tzanko S StantchevDivision of Biotechnology Review and Research 1 (DBRR1), Office of Biotechnology Products (OBP), Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA), Silver Spring, MD 20993, USA. tzanko.stantchev@fda.hhs.gov.
Autumn Zack-TaylorDivision of Biotechnology Review and Research 1 (DBRR1), Office of Biotechnology Products (OBP), Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA), Silver Spring, MD 20993, USA. autumn.zack-taylor@fda.hhs.gov.
Nicholas MattsonDivision of Biotechnology Review and Research 1 (DBRR1), Office of Biotechnology Products (OBP), Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA), Silver Spring, MD 20993, USA. nicholas.mattson@fda.hhs.gov.
Klaus StrebelLaboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD 20814, USA. kstrebel@niaid.nih.gov.
Christopher C BroderDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences (USUHS), Bethesda, MD 20814, USA. christopher.broder@usuhs.edu.ORCID 0000-0001-5382-0510
Kathleen A ClouseDivision of Biotechnology Review and Research 1 (DBRR1), Office of Biotechnology Products (OBP), Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA), Silver Spring, MD 20993, USA. kathleen.clouse@fda.hhs.gov.
United States Food and Drug Administration · USNational Institutes of Health · USUniformed Services University of the Health Sciences · US

Funding

FDA HHS OCET 2015916
6 · The paper itself

Abstract

Macrophages are one of the first and also a major site of filovirus replication and, in addition, are a source of multiple cytokines, presumed to play a critical role in the pathogenesis of the viral infection. Some of these cytokines are known to induce macrophage phenotypic changes in vitro, but how macrophage polarization may affect the cell susceptibility to filovirus entry remains largely unstudied. We generated different macrophage subsets using cytokine pre-treatment and subsequently tested their ability to fuse with beta-lactamase containing virus-like particles (VLP), pseudotyped with the surface glycoprotein of Ebola virus (EBOV) or the glycoproteins of other clinically relevant filovirus species. We found that pre-incubation of primary human monocyte-derived macrophages (MDM) with interleukin-10 (IL-10) significantly enhanced filovirus entry into cells obtained from multiple healthy donors, and the IL-10 effect was preserved in the presence of pro-inflammatory cytokines found to be elevated during EBOV disease. In contrast, fusion of IL-10-treated macrophages with influenza hemagglutinin/neuraminidase pseudotyped VLPs was unchanged or slightly reduced. Importantly, our in vitro data showing enhanced virus entry are consistent with the correlation established between elevated serum IL-10 and increased mortality in filovirus infected patients and also reveal a novel mechanism that may account for the IL-10-mediated increase in filovirus pathogenicity.

Indexed as

Cells, CulturedCytokinesEbolavirusFiloviridaeFiloviridae InfectionsHumansInterleukin-10MacrophagesMembrane FusionViral Envelope ProteinsVirus InternalizationCytokinesInterleukin-10Viral Envelope ProteinscytokinesEbola virus (EBOV)filovirusesinterleukin-10 (IL-10)

Identifiers

PMID31547585
PMCPMC6832363
OpenAlexW2973741758

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.